Status In progress
Process STA
ID number 937

Provisional Schedule

Expected publication 25 July 2018

Project Team

Project lead Donna Barnes

Email enquiries


Companies sponsors Roche
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Multiple Sclerosis Society
  Multiple Sclerosis Trust
Professional groups Royal College of Physicians
  UK Clinical Pharmacy Association


Comparator companies Bayer (interferon beta 1b) (CA&U not returned, not participating)
  Biogen Idec (daclizumab, dimethyl fumarate, interferon beta 1a, natalizumab, peginterferon beta 1a)
  Genzyme (alemtuzumab, teriflunomide)
  Merck Serono (interferon beta 1a)
  Novartis (interferon beta 1b, fingolimod)
  Teva UK (glatiramer acetate)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups None


Key events during the development of the guidance:

Date Update
06 March 2018 Committee meeting: 1
02 October 2017 Invitation to participate
23 June 2017 Following on from advice received from the company this appraisal has been rescheduled. Therefore, we now anticipate that the appraisal will begin during late September 2017 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late November 2017.
24 January 2017 Draft scope documents
05 December 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance